These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25361812)

  • 1. Preclinical efficacy of MEK inhibition in Nras-mutant AML.
    Burgess MR; Hwang E; Firestone AJ; Huang T; Xu J; Zuber J; Bohin N; Wen T; Kogan SC; Haigis KM; Sampath D; Lowe S; Shannon K; Li Q
    Blood; 2014 Dec; 124(26):3947-55. PubMed ID: 25361812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.
    Pomeroy EJ; Lee LA; Lee RDW; Schirm DK; Temiz NA; Ma J; Gruber TA; Diaz-Flores E; Moriarity BS; Downing JR; Shannon KM; Largaespada DA; Eckfeldt CE
    Oncogene; 2017 Jun; 36(23):3263-3273. PubMed ID: 27991934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis.
    Xue L; Pulikkan JA; Valk PJ; Castilla LH
    Blood; 2014 Jul; 124(3):426-36. PubMed ID: 24894773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study.
    Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y
    BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A gain-of-function p53 mutant synergizes with oncogenic NRAS to promote acute myeloid leukemia in mice.
    Rajagopalan A; Feng Y; Gayatri MB; Ranheim EA; Klungness T; Matson DR; Lee MH; Jung MM; Zhou Y; Gao X; Nadiminti KV; Yang DT; Tran VL; Padron E; Miyamoto S; Bresnick EH; Zhang J
    J Clin Invest; 2023 Dec; 133(24):. PubMed ID: 37847561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
    Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
    Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Zhang J; Kong G; Rajagopalan A; Lu L; Song J; Hussaini M; Zhang X; Ranheim EA; Liu Y; Wang J; Gao X; Chang YI; Johnson KD; Zhou Y; Yang D; Bhatnagar B; Lucas DM; Bresnick EH; Zhong X; Padron E; Zhang J
    Blood; 2017 Jan; 129(3):358-370. PubMed ID: 27815262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
    Kim WI; Matise I; Diers MD; Largaespada DA
    Blood; 2009 Jan; 113(5):1086-96. PubMed ID: 18952898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells.
    An N; Khan S; Imgruet MK; Jueng L; Gurbuxani S; McNerney ME
    Oncogene; 2023 Mar; 42(12):881-893. PubMed ID: 36725889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A; Kraft M; Eliasson P; Labi V; Lam EW; Villunger A; Jönsson JI
    Blood; 2009 Mar; 113(10):2302-11. PubMed ID: 19064725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.
    Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H
    Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
    You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y; Finke C; Mangaonkar A; Liao R; Kong G; Ranheim EA; Droin N; Hunter AM; Nikolaev S; Balasis M; Abdel-Wahab O; Levine RL; Will B; Nadiminti KVG; Yang D; Geissler K; Solary E; Xu W; Padron E; Patnaik MM; Zhang J
    Blood; 2022 Feb; 139(7):1066-1079. PubMed ID: 34699595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
    Posch C; Moslehi H; Feeney L; Green GA; Ebaee A; Feichtenschlager V; Chong K; Peng L; Dimon MT; Phillips T; Daud AI; McCalmont TH; LeBoit PE; Ortiz-Urda S
    Proc Natl Acad Sci U S A; 2013 Mar; 110(10):4015-20. PubMed ID: 23431193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nras(G12D/+) promotes leukemogenesis by aberrantly regulating hematopoietic stem cell functions.
    Wang J; Kong G; Liu Y; Du J; Chang YI; Tey SR; Zhang X; Ranheim EA; Saba-El-Leil MK; Meloche S; Damnernsawad A; Zhang J; Zhang J
    Blood; 2013 Jun; 121(26):5203-7. PubMed ID: 23687087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells.
    Jin X; Qin T; Zhao M; Bailey N; Liu L; Yang K; Ng V; Higashimoto T; Coolon R; Ney G; Figueroa ME; Li Q
    Blood Adv; 2018 Jun; 2(11):1259-1271. PubMed ID: 29866713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
    Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
    Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
    Wen Z; Yun G; Hebert A; Kong G; Ranheim EA; Finn R; Rajagoplan A; Li S; Zhou Y; Yu M; Damnernsawad A; Roose JP; Coon JJ; Wen R; Wang D; Zhang J
    Blood; 2021 Jun; 137(23):3259-3271. PubMed ID: 33512434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First SAR Study for Overriding NRAS Mutant Driven Acute Myeloid Leukemia.
    Cho H; Shin I; Ju E; Choi S; Hur W; Kim H; Hong E; Kim ND; Choi HG; Gray NS; Sim T
    J Med Chem; 2018 Sep; 61(18):8353-8373. PubMed ID: 30153003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C57BL/6 congenic mouse NRAS
    Petit V; Raymond J; Alberti C; Pouteaux M; Gallagher SJ; Nguyen MQ; Aplin AE; Delmas V; Larue L
    Pigment Cell Melanoma Res; 2019 Nov; 32(6):829-841. PubMed ID: 31251472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.